Clinical and Experimental Medicine最新文献

Sarcopenic visceral obesity in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). 代谢功能障碍相关脂肪变性肝病（MASLD）患者的肌肉减少性内脏肥胖

IF 3.5 4区医学

Clinical and Experimental Medicine Pub Date : 2025-10-21 DOI: 10.1007/s10238-025-01865-y

Maha Elsabaawy, Amr Ragab, Amal Abd-Elrazek, Mohamed Atef, Madiha Naguib

{"title":"Sarcopenic visceral obesity in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).","authors":"Maha Elsabaawy, Amr Ragab, Amal Abd-Elrazek, Mohamed Atef, Madiha Naguib","doi":"10.1007/s10238-025-01865-y","DOIUrl":"https://doi.org/10.1007/s10238-025-01865-y","url":null,"abstract":"Sarcopenic visceral obesity (SVO) has emerged as a high-risk metabolic phenotype in metabolic dysfunction-associated steatotic liver disease (MASLD). This study aimed to define the prevalence and metabolic implications of MRI-defined SVO in MASLD, evaluate its association with liver fibrosis, cardiovascular risk, and introduce a novel tier-based classification for risk stratification. In this cross-sectional study, 334 adults with MASLD underwent comprehensive phenotyping. Sarcopenia was assessed by bioelectrical impedance analysis, while visceral obesity was quantified via MRI-based visceral fat area (VFA ≥ 100 cm2). Liver fibrosis was evaluated using non-invasive indices and confirmed in a subset by magnetic resonance elastography (MRE). Participants were stratified into SVO and non-SVO groups, and further categorized into Red, Yellow, or Green tiers based on fibrosis stage and cardiovascular risk. SVO was present in 42.5% of MASLD patients, with higher prevalence among women and individuals with BMI ≥ 40. SVO was associated with significantly worse metabolic profiles (HOMA-IR: 6.2 ± 2.8, p < 0.001), advanced fibrosis (FIB-4: 2.3 ± 1.4, p = 0.003), and higher cardiovascular risk (ASCVD ≥ 7.5%: 65%, p < 0.001). In multivariate analysis, SVO independently predicted advanced fibrosis (OR = 2.5, p = 0.002). Importantly, a tier-based classification model identified a high-risk \"Red Tier\" group (100% F3-F4 fibrosis, 100% diabetes). This is the first study in a Middle Eastern MASLD cohort to combine MRI-based adiposity assessment with validated sarcopenia criteria to define SVO and demonstrate its prognostic relevance. The introduction of a tiered risk framework integrating SVO, fibrosis, and ASCVD risk represents a novel approach to personalized MASLD care and support targeted decision-making.","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"25 1","pages":"316"},"PeriodicalIF":3.5,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145336739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interferon alpha-induced uPAR expression on monocytes as a potential source of increased soluble uPAR in patients with SLE at high risk of developing organ damage. 干扰素α诱导的uPAR在单核细胞上的表达是SLE患者发生器官损伤高风险时可溶性uPAR增加的潜在来源。

IF 3.5 4区医学

Clinical and Experimental Medicine Pub Date : 2025-10-21 DOI: 10.1007/s10238-025-01897-4

Lina Wirestam, Jesper Karlsson, Astrid Welin, Jhonatan Antonio Álvarez-Gómez, Jonas Wetterö, Christopher Sjöwall, Helena Enocsson

{"title":"Interferon alpha-induced uPAR expression on monocytes as a potential source of increased soluble uPAR in patients with SLE at high risk of developing organ damage.","authors":"Lina Wirestam, Jesper Karlsson, Astrid Welin, Jhonatan Antonio Álvarez-Gómez, Jonas Wetterö, Christopher Sjöwall, Helena Enocsson","doi":"10.1007/s10238-025-01897-4","DOIUrl":"https://doi.org/10.1007/s10238-025-01897-4","url":null,"abstract":"The soluble urokinase plasminogen activator receptor (suPAR) has been shown to adequately predict the risk of organ damage development in patients with systemic lupus erythematosus (SLE). However, the cellular source and mechanism of increased circulating levels remain unknown. The cell-bound uPAR is expressed on various cell types and can be shed from the plasma membrane surface by proteases, resulting in the soluble form, suPAR. Herein, leukocyte uPAR expression and plasma suPAR levels were explored in unstimulated and cytokine-treated (tumor necrosis factor; TNF or interferon-α; IFN-α) blood from patients with SLE (n = 37) and healthy blood donors (HBD; n = 27). Unstimulated or cytokine-treated whole blood was thereafter used for analysis of cellular uPAR expression by flow cytometry, and plasma suPAR levels by enzyme-linked immunosorbent assay (ELISA). Monocytes and neutrophils had the most prominent uPAR expression and showed increased expression after TNF addition to the blood (p < 0.001). Addition of IFN-α resulted in increased uPAR expression only in patients (p < 0.05). No differences in uPAR expression were found depending on organ damage or other clinical variables. Nevertheless, suPAR levels were higher in patients with organ damage (p < 0.01). Unstimulated suPAR levels were correlated with monocyte uPAR expression in patient samples (rho = 0.4). As circulating suPAR levels can predict organ damage development in SLE, it is important to unravel its potential disease mediating effects as well as cellular sources. Results of this study suggest IFN-α as a regulator of uPAR expression in SLE and monocyte uPAR as an important source of plasma suPAR.","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"25 1","pages":"317"},"PeriodicalIF":3.5,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145336745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The discovery of Bevacizumab. An historical reappraisal. 贝伐单抗的发现。对历史的重新评价。

IF 3.5 4区医学

Clinical and Experimental Medicine Pub Date : 2025-10-17 DOI: 10.1007/s10238-025-01857-y

Domenico Ribatti

引用次数: 0

Prevalence of sacroiliitis on magnetic resonance enterography in Crohn's disease and its association with intestinal findings: a monocentric observational cross-sectional study. 克罗恩病的骶髂炎的磁共振肠造影患病率及其与肠道表现的关系：一项单中心观察性横断面研究

IF 3.5 4区医学

Clinical and Experimental Medicine Pub Date : 2025-09-04 DOI: 10.1007/s10238-025-01846-1

G Amati, G Sandri, A Bertani, D Vaccari, A Pecchi, B Bongiovanni, M Orlandi, G Ciancio, M Pecchini, O Secchi, A Colecchia, P Torricelli, D Giuggioli

{"title":"Prevalence of sacroiliitis on magnetic resonance enterography in Crohn's disease and its association with intestinal findings: a monocentric observational cross-sectional study.","authors":"G Amati, G Sandri, A Bertani, D Vaccari, A Pecchi, B Bongiovanni, M Orlandi, G Ciancio, M Pecchini, O Secchi, A Colecchia, P Torricelli, D Giuggioli","doi":"10.1007/s10238-025-01846-1","DOIUrl":"10.1007/s10238-025-01846-1","url":null,"abstract":"Magnetic resonance enterography (MRE) is recommended for the assessment of small intestine alterations in Crohn's disease (CD). Sacroiliac joints (SIJs) imaging has a central role in the early diagnosis of sacroiliitis (SI). MRE can evaluate both acute and structural findings of SIJs. We aimed to assess the prevalence of SI detected by MRE in a cohort of CD patients, and the associations of SI with demographic and clinical features and with intestinal MRE findings. Two hundred patients affected by CD (M:F 1:1, median age 49.5 (22.5) years, median CD duration 4.75 (16.2) years) tested with MRE between 2011 and 2023 were selected. They discontinued tumor necrosis factor α inhibitors (TNFαi) at least 3 months before the MRE execution. Most patients had an ileal CD location (65.0%) and a stricturing behavior of disease (50.0%). Thirty-five percent of patients underwent ileocecal resection. One out of ten patients were treated with at least one TNFαi. Active SI, capsulitis, erosions, sclerosis, and ankylosis were present in 10.5%, 0.5%, 2.0%, 2.5%, and 1.5%, respectively. No significant correlations have been evidenced between the presence of SI and demographic and clinical variables. The presence of an asymmetric hyperenhancement of the bowel wall was instead directly associated with the presence of SI (OR 8.61, 95% CI 1.47-50.4, p = 0.017). In this study, subclinical SI is a frequent finding in CD patients being present in one out of ten MRE examination. This phenomenon was significantly associated with asymmetric mural enhancement, a specific CD intestinal lesion at MRE.","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"25 1","pages":"314"},"PeriodicalIF":3.5,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12408789/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Implementation effects of quality control circle in improving medication adherence of outpatient helicobacter pylori patients. 品管圈在提高门诊幽门螺杆菌患者服药依从性中的实施效果。

IF 3.5 4区医学

Clinical and Experimental Medicine Pub Date : 2025-09-03 DOI: 10.1007/s10238-025-01864-z

Huan Gu, Huadong Jiang

{"title":"Implementation effects of quality control circle in improving medication adherence of outpatient helicobacter pylori patients.","authors":"Huan Gu, Huadong Jiang","doi":"10.1007/s10238-025-01864-z","DOIUrl":"10.1007/s10238-025-01864-z","url":null,"abstract":"To evaluate the implementation effects of problem-solving Quality Control Circle (QCC) activities on medication adherence among outpatient Helicobacter pylori patients. Pharmacists collected data scales, guidance sheets, registration forms, and scoring sheets from outpatient H. pylori patients from January to March 2024. Through brainstorming, factors affecting medication adherence were identified and a series of specific measures were formulated. Implementation was carried out from April to July 2024, and the therapeutic effects of patients before and after implementing the QCC process were evaluated. The total score of patient medication adherence improved from 7.9 to 9.2, with statistically significant results (P < 0.001). The medication compliance rate increased from 57.46% to 87.62%; the adverse reaction incidence decreased from 39 to 11%; the C14 breath test positive rate decreased from 67.2% to 30.65%. All the above results showed statistically significant differences (P < 0.001). Implementing QCC can standardize and improve medication adherence measures for H. pylori patients, which has practical significance for patient treatment outcomes, while also enhancing pharmacists' professional knowledge and skills.","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"25 1","pages":"313"},"PeriodicalIF":3.5,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12405293/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comprehensive analysis of KRT18 as a novel prognostic biomarker and potential target in lung adenocarcinoma. KRT18作为肺腺癌新的预后生物标志物和潜在靶点的综合分析。

IF 3.5 4区医学

Clinical and Experimental Medicine Pub Date : 2025-09-01 DOI: 10.1007/s10238-025-01855-0

Jiajia Xiao, Zhenpeng Zhu, Fengxu Yan, Zhicong Yang, Dandan Xu, Fan Zhang, Xinsheng Wang

{"title":"Comprehensive analysis of KRT18 as a novel prognostic biomarker and potential target in lung adenocarcinoma.","authors":"Jiajia Xiao, Zhenpeng Zhu, Fengxu Yan, Zhicong Yang, Dandan Xu, Fan Zhang, Xinsheng Wang","doi":"10.1007/s10238-025-01855-0","DOIUrl":"10.1007/s10238-025-01855-0","url":null,"abstract":"Background: The expression characteristics of Keratin 18 (KRT18) in lung adenocarcinoma (LUAD) remain incompletely elucidated. This study aims to investigate the expression pattern of KRT18 in LUAD and its prognostic significance.Methods: We analyzed the expression status of KRT18 in LUAD and its association with prognosis. Utilizing the UALCAN and STRING databases, we systematically evaluated the clinical phenotypic parameters of KRT18 and its protein-protein interaction network. Through enrichment analysis, we clarified its biological functions and associated signaling pathways, and simultaneously deciphered the association patterns between the tumor immune infiltration landscape and immune checkpoint molecules.Results: High expression of KRT18 was associated with poor prognosis in LUAD patients and was closely correlated with tumor stage and pathological stage. Functional enrichment analysis revealed that KRT18 was significantly enriched in epithelial cell differentiation and intermediate filament pathways. Immune infiltration analysis showed that the expression of KRT18 was associated with tumor immune cell infiltration and immune checkpoints. Immunohistochemistry further confirmed the high expression of KRT18 in LUAD tissues.Conclusion: Therefore, KRT18 may serve as a biomarker for the prognosis and diagnosis of LUAD and also represents a potential target for immunotherapy.","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"25 1","pages":"312"},"PeriodicalIF":3.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12401774/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The dual burden of tuberculosis and diabetes mellitus: an epidemiological correlation. 肺结核和糖尿病的双重负担：流行病学相关性。

IF 3.5 4区医学

Clinical and Experimental Medicine Pub Date : 2025-08-31 DOI: 10.1007/s10238-025-01797-7

Salma Bibi, Hayat Khan, Muhammad Salman, Jadoon Khan, Tawaf Ali Shah, Molalign Assefa, Hesham M Hassan

{"title":"The dual burden of tuberculosis and diabetes mellitus: an epidemiological correlation.","authors":"Salma Bibi, Hayat Khan, Muhammad Salman, Jadoon Khan, Tawaf Ali Shah, Molalign Assefa, Hesham M Hassan","doi":"10.1007/s10238-025-01797-7","DOIUrl":"https://doi.org/10.1007/s10238-025-01797-7","url":null,"abstract":"This study examined the association between diabetes mellitus and tuberculosis (TB) in a cohort of 200TB-positive patients, stratified by gender, age, treatment regimen, and comorbidities, including diabetes, acute gastroenteritis, and hypertension, compared to TB patients without additional complications. Clinical parameters-Random Blood Sugar (RBS), C-reactive protein (CRP), and Erythrocyte Sedimentation Rate (ESR)-were assessed at baseline and after four months of anti-TB therapy. The results showed no significant changes in mean RBS or CRP levels post-treatment, but a notable reduction in mean ESR was observed. Age and gender had minimal impact on therapeutic outcomes for RBS, CRP, or ESR, though females exhibited higher ESR values than males. Treatment regimens, whether Myrin P Forte alone or combined with streptomycin, did not significantly alter clinical parameters. However, CRP levels improved in TB patients with comorbidities, such as diabetes, hypertension, or gastroenteritis. A significant prevalence of diabetes (21.42%) was found among TB patients, with higher rates in females and those over 50 years. These findings highlight a notable association between diabetes and TB. However, the minimal effect of anti-TB therapy on clinical parameters suggests that ESR and CRP may not be reliable prognostic markers for TB. The study underscores the need for further large-scale case-control studies and molecular research to better understand the relationship between diabetes and TB, particularly given the high prevalence of diabetes among TB patients.","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"25 1","pages":"308"},"PeriodicalIF":3.5,"publicationDate":"2025-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12399438/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Identification and validation of prognostic genes associated with mitochondrial nuclear genes in gastric cancer. 胃癌线粒体核基因相关预后基因的鉴定与验证。

IF 3.5 4区医学

Clinical and Experimental Medicine Pub Date : 2025-08-31 DOI: 10.1007/s10238-025-01844-3

Cong Fu, Lin Sun, Xiaoyue Zhou, Tong Zhou, Yanzhi Bi

{"title":"Identification and validation of prognostic genes associated with mitochondrial nuclear genes in gastric cancer.","authors":"Cong Fu, Lin Sun, Xiaoyue Zhou, Tong Zhou, Yanzhi Bi","doi":"10.1007/s10238-025-01844-3","DOIUrl":"https://doi.org/10.1007/s10238-025-01844-3","url":null,"abstract":"Mitochondrial-related nuclear genes (MNGs) have shown great importance in cancer diagnosis and prognosis, but their role in gastric cancer (GC) remains unclear. GC-related transcriptome data from the gene expression omnibus and cancer genome atlas databases were analyzed to identify differentially expressed MNGs. A prognostic risk model was constructed through univariate Cox and least absolute shrinkage and selection operator regression, validated by Kaplan-Meier (K-M) survival curve and receiver operating characteristic curve. This was followed by immune infiltration analysis, independent prognostic analysis, functional enrichment analysis, drug sensitivity analysis, drug prediction, molecular docking and construction of regulatory networks. Three prognostic genes (ATP8A2, COX15 and TARS2) were identified. The expression of TARS2 and COX15 was positively correlated with CNV, while ATP8A2 was unaffected. The risk model and nomogram, integrating risk score and clinicopathological factors, exhibited excellent predictive performance. A significant correlation was observed between prognostic genes and differential immune cells, such as T cells, B cells, and NK cells. BMS-754807, Gefitinib, JQ1, Lapatinib, and Sapitinib exhibited significant differences in sensitivity between the high-risk group and the low-risk group. The results of molecular docking showed TP8A2 has stable binding ability with cytosine, COX15 with indomethacin, and TARS2 with bisacodyl. RT-qPCR revealed downregulation of ATP8A2 and upregulation of COX15 and TARS2 in GC samples. MNGs, including ATP8A2, COX15, and TARS2, demonstrated significant associations with immune infiltration, CNV, and prognostic outcomes of GC.","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"25 1","pages":"309"},"PeriodicalIF":3.5,"publicationDate":"2025-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12399450/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical characteristics and management of paroxysmal nocturnal hemoglobinuria in the Middle East: a narrative review. 中东地区阵发性夜间血红蛋白尿的临床特点和治疗：叙述性回顾。

IF 3.5 4区医学

Clinical and Experimental Medicine Pub Date : 2025-08-31 DOI: 10.1007/s10238-025-01834-5

Mohammed Almakadi, Noura AlHashim, Murtadha Al-Khabori, Hazzaa Alzahrani, Hani Yousif Osman, Mervat Mattar, Ahmed Sabah

{"title":"Clinical characteristics and management of paroxysmal nocturnal hemoglobinuria in the Middle East: a narrative review.","authors":"Mohammed Almakadi, Noura AlHashim, Murtadha Al-Khabori, Hazzaa Alzahrani, Hani Yousif Osman, Mervat Mattar, Ahmed Sabah","doi":"10.1007/s10238-025-01834-5","DOIUrl":"https://doi.org/10.1007/s10238-025-01834-5","url":null,"abstract":"Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematological disorder caused by uncontrolled terminal complement activation of blood cells. It is associated with intravascular hemolysis, thromboembolic events, organ damage, impaired quality of life and premature mortality. As there are no PNH registry data from Middle Eastern countries, little is known about its management in the region. This narrative review summarizes available data on the prevalence, characteristics, diagnosis and treatment of PNH in Middle Eastern populations of Arabic origin. A search of PubMed and EMBASE from inception to 31 May 2025 identified 15 relevant publications: five from Saudi Arabia, four from Iran, two from Kuwait, one each from Egypt, Oman, Lebanon, and one reporting a Middle Eastern patient treated in Germany. The estimated incidence rate of PNH in an Omani cohort was 1.9 per 5 million population. Mean and median ages at PNH diagnosis were 38 years (Iranian retrospective review, n = 81) and 22.5 years (Omani case series, n = 10), respectively. Where reported, anemia and fatigue were common presenting symptoms. Few publications reported on treatment with C5 inhibitors, although available data indicate that eculizumab generally improves patients' clinical condition. Uptake and clinical use of ravulizumab in the Middle East remains undocumented. Subject to limitations of the available data, the management approach to PNH in the Middle East appears to be generally consistent with that reported in other regions. However, additional data are required to gain greater insight into the status of PNH and its management in Middle Eastern populations.","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"25 1","pages":"310"},"PeriodicalIF":3.5,"publicationDate":"2025-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12399696/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrating multi-omics approaches in acute myeloid leukemia (AML): Advancements and clinical implications. 整合多组学方法治疗急性髓性白血病（AML）：进展和临床意义。

IF 3.5 4区医学

Clinical and Experimental Medicine Pub Date : 2025-08-31 DOI: 10.1007/s10238-025-01858-x

Hamed Soleimani Samarkhazan

{"title":"Integrating multi-omics approaches in acute myeloid leukemia (AML): Advancements and clinical implications.","authors":"Hamed Soleimani Samarkhazan","doi":"10.1007/s10238-025-01858-x","DOIUrl":"https://doi.org/10.1007/s10238-025-01858-x","url":null,"abstract":"Acute myeloid leukemia (AML) is a highly heterogeneous and aggressive hematologic malignancy characterized by clonal proliferation of myeloid precursors. Despite significant advancements in genomic profiling and targeted therapies, patient outcomes remain suboptimal due to disease complexity, resistance mechanisms, and high relapse rates. The integration of multi-omics approaches-spanning genomics, epigenomics, transcriptomics, proteomics, and metabolomics-has revolutionized AML research, offering a comprehensive understanding of leukemogenesis, tumor heterogeneity, and therapeutic vulnerabilities. Recent studies leveraging high-throughput sequencing, mass spectrometry, and advanced computational tools have uncovered novel biomarkers, clonal evolution dynamics, and microenvironmental interactions that drive AML progression and resistance. For instance, single-cell multi-omics has revealed chemotherapy-resistant leukemic stem cell populations, while proteogenomic analyses have identified actionable targets such as MCL1 and metabolic dependencies like OXPHOS. Clinically, integrated omics platforms are refining risk stratification, minimal residual disease (MRD) monitoring, and personalized therapy selection. However, challenges such as data integration complexity, cost barriers, and ethical considerations remain. This review highlights the transformative potential of multi-omics in AML, emphasizing recent advancements in technology, biomarker discovery, and therapeutic innovation. By bridging the gap between molecular insights and clinical practice, multi-omics integration promises to redefine AML management, paving the way for precision oncology and improved patient outcomes.","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"25 1","pages":"311"},"PeriodicalIF":3.5,"publicationDate":"2025-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12399717/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0